Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

Definium Therapeutics Announces New Employee Inducement Grants

Today 7:01 EST

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

Performance

52-Week Range 28.8% below 52-week high

35.39

14.6252W Low 49.7052W High

1 Week 3.9% below 1-week high

30.171W Low 36.841W High

Definium Therapeutics, Inc. - Common Shares (DFTX) traded between $14.62 and $49.70 over the past 52 weeks and last traded at $35.39, 28.8% below its 52-week high. Over the past week it ranged between $30.17 and $36.84.

Past 12 Months

+9.0%

-4.1%

-21.6%

+65.4%

+130.1%

1W +$2.92

1M -$1.51

3M -$9.76

6M +$13.99

YTD +$20.01

1Y +$20.01

DFTX was +130.1% over the past year, +65.4% over six months, +130.1% year to date, +9.0% in the last week.

12 Months vs Market

DFTX

+130.1%

DIA

+10.4%

SPY

+10.5%

QQQ

+9.0%

IWM

+15.8%

Over the past 12 months DFTX returned +130.1% versus DIA (Dow) +10.4%, SPY (S&P 500) +10.5%, QQQ (Nasdaq 100) +9.0% and IWM (Russell 2000) +15.8%.

Volume & Liquidity 0.65× 3-mo avg

Today 1,413,997 3-mo avg 2.2M

2.0M

1.9M

2.2M

2.5M

YTD

2.2M

DFTX most recently traded 1,413,997 shares against a 3-month average daily volume of 2.2M.

More News

November 04, 2026

Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗

August 06, 2026

Via Chartmill

Definium Therapeutics to Participate at Upcoming Investor Conferences

November 03, 2026

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

October 29, 2026

Definium Therapeutics Announces New Employee Inducement Grants

October 26, 2026

Definium Therapeutics Announces New Employee Inducement Grants

October 13, 2026

Definium Therapeutics Announces New Employee Inducement Grants

September 28, 2026

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression ↗

September 24, 2026

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study ↗

September 19, 2026

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

September 14, 2026

Definium Therapeutics Announces New Employee Inducement Grants

September 14, 2026

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

September 13, 2026

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

September 10, 2026

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

September 08, 2026

Definium Therapeutics Announces New Employee Inducement Grants

August 31, 2026

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

August 26, 2026

Definium Therapeutics Announces New Employee Inducement Grants

August 17, 2026

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗

August 13, 2026

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Wondering what's happening in today's pre-market session? ↗

August 12, 2026

Via Chartmill

August 12, 2026

Definium Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026